Targeting the a4-a5 dimerization interface of K-RAS inhibits tumor formation in vivo.

Targeting the a4-a5 dimerization interface of K-RAS inhibits tumor formation in vivo. Oncogene. 2019 04; 38(16):2984-2993.

View in: PubMed